Agios Pharmaceuticals AGIO Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Bristol-Myers SquibbBMY

——

PfizerPFE

——

Vertex PharmaceuticalsVRTX

——

IncyteINCY

——

BioMarin PharmaceuticalsBMRN

——

Disc MedicineIRON

——

Other financials

Income statement

See full

Revenue$20.7M+138%

Gross profit$19.4M+154%

Operating income-$110.0M-3.2%

Net income-$99.1M-11.0%

EPS (diluted)-$1.69-9.0%

Balance sheet

See full

Cash & equivalents$113.6M+43.9%

Total debt$35.7M-32.5%

Total equity$1.1B-24.4%

Total assets$1.2B-23.8%

Cash flow

See full

Operating cash flow-$118.9M-6.7%

CapEx$769.0K+0.4%

Free cash flow-$119.7M-6.6%

Valuation

See full

Market cap$2.12B+18.1%

Enterprise value$2.04B+15.2%

P/S32.1×-16.4×

Profitability

See full

Gross margin90%+2.5pp

Operating margin-720%-204pp

Net margin-639.8%—

FCF margin-582.5%-185pp

Returns & leverage

See full

Return on equity-32.8%—

Debt / equity0×0.0×

Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Agios Pharmaceuticals's software and technology licenses, net?: Agios Pharmaceuticals (AGIO) reported software and technology licenses, net of $3.93M in Q1 2026.
How has Agios Pharmaceuticals's software and technology licenses, net changed year-over-year?: Agios Pharmaceuticals's software and technology licenses, net decreased by 16.7% year-over-year, from $4.72M to $3.93M.